Medtronic Announces Final Exchange Ratio of 4.5939 in Split-Off of MiniMed Group, Inc.

Medtronic set the final exchange ratio for its offer to exchange Medtronic ordinary shares for MiniMed common stock at 4.5939 MiniMed shares per Medtronic share, the offer’s upper limit. If oversubscribed, Medtronic currently intends to exchange its remaining 27,452,053 MiniMed shares as well as the 225,361,295 shares initially offered; that could mean accepting approximately 55.0 million Medtronic shares, versus approximately 49.1 million if it does not increase the amount accepted. The offer and withdrawal rights expire at midnight New York time on October 9, 2026, unless extended or terminated, and oversubscription may result in proration.

Analysis

The binding economic question is not the headline ratio itself but whether the market value of 4.5939 MMED shares compensates for surrendering one MDT share after allowing for proration, execution costs, and any tax or operational frictions described in the prospectus. Because the calculated ratio exceeded the cap, the cap may make participation less attractive than an uncapped value-based exchange would have been; verify the offer’s exact valuation formula and compare live prices before treating this as a clean arbitrage. No market prices or expected proration rate are supplied, so there is no defensible standalone spread estimate.

Near term, tendering creates allocation uncertainty: oversubscription can leave holders with both residual MDT and a smaller-than-intended MMED position, complicating hedges around the October 9 deadline and subsequent settlement. The exchange transfers existing MMED shares rather than signaling a primary capital raise; a larger public float could improve tradability over time, but recipients’ portfolio rebalancing may add near-term supply. Over 1–3 months, completion and separation disclosures matter more than the ratio announcement. Over 6–18 months, the key test is whether MMED can establish a credible standalone operating and capital-allocation profile; the release provides no financial detail to underwrite that outcome. The thesis weakens if the offer is extended or altered, the separation is delayed, or MMED’s post-offer trading value persistently underperforms the exchange-implied value.

Key Decisions for Investors

• Before the October 9 expiry, calculate the live value of 4.5939 MMED shares versus one MDT share, using the prospectus valuation terms and including fees, taxes where relevant to the fund, settlement timing, and expected proration. Do not infer an arbitrage from the capped ratio alone.
• For event-driven books, treat a long-MMED/short-MDT hedge only as a conditional basis trade: size against realistic proration scenarios and confirm MMED borrow availability and liquidity first. Missing inputs are current prices, tender participation, borrow cost, and settlement mechanics; without them, keep it on watch rather than initiate.
• Avoid making a fundamental long or short call on either company from this announcement. Reassess after the offer result and separation filings, focusing on MMED’s standalone financial disclosures and MDT’s guidance for the retained businesses.
• Monitor for falsification: an amended or delayed offer, a materially different acceptance/proration outcome, separation conditions failing, or post-completion MMED weakness versus its exchange-implied value would invalidate the near-term event thesis.